Complete Response in Advanced Uterine Clear Cell Carcinoma: A Case Analysis
Author Information
Author(s): Chen Yue, Zhou Wenting, Wang Yili
Primary Institution: The Oncology Department of the First Affiliated Hospital of Gannan Medical University
Hypothesis
Can a combination of paclitaxel albumin-bound and PD-1/CTLA-4 bispecific antibody effectively treat advanced uterine clear cell carcinoma?
Conclusion
The combination treatment led to a complete response in a patient with advanced uterine clear cell carcinoma, suggesting its potential effectiveness.
Supporting Evidence
- The patient achieved complete remission after treatment with cadonilimab and albumin-bound paclitaxel.
- The treatment was well-tolerated despite some adverse effects.
- The patient's response was maintained during follow-up examinations.
Takeaway
A woman with a tough type of cancer got better after using a special medicine combined with chemotherapy, showing that new treatments can work well.
Methodology
The patient received a combination of cadonilimab and albumin-bound paclitaxel for six cycles, followed by cadonilimab monotherapy.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
49-year-old female with a history of atrial fibrillation and advanced uterine clear cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website